ClinicalTrials.gg
CompletedNCT04487236Updated Aug 11, 2025

Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid Tumors

A Phase 1 interventional study of ZN-A-1041 50mg BID and ZN-A-1041 100mg BID in Advanced Solid Tumors and HER2-positive Breast Cancer, sponsored by Suzhou Zanrong Pharma Limited. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-11.

Sponsored by Suzhou Zanrong Pharma Limited · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
61
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 179 studies in Brain Neoplasms with a site in China — 72 open to participants now, 83 under way, 6 of them phase 3. Brain Neoplasms · China.

Enrollment
64th of 142
61 · median 60
Started
2020
with 15 others
Phase 1
17 of 179
8 open now
Registered
68th of 179
by date

Among the 179 studies in Brain Neoplasms with a site in China, this one is the 64th largest by enrollment of the 142 interventional ones that give a count, is one of 16 that started in 2020, is one of 17 in phase 1, and was the 68th registered.

Brain Neoplasms

2,442 studies on the registry are indexed under Brain Neoplasms; 543 are open to participants now.

Browse Brain Neoplasms studies →

Open to participants now

72 of the 179 studies in Brain Neoplasms with a site in China are open now. Recruiting first, the newest first:

67 more — sign in →

All 72 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 427 Brain Neoplasms studies recruiting now, 287 (67%) set no upper age limit and 82 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 179 studies in Brain Neoplasms with a site in China, or all of them as a file.
02

Study summary

This will be a phase 1, multicenter, open-label trial to evaluate the safety, tolerability, PK and efficacy of ZN-A-1041 as a monotherapy or in combination in patients with HER2-positive advanced solid tumors.

The study will consist of three phases: phase 1a (dose escalation with ZN-A-1041 monotherapy), phase 1b (dose escalation with ZN-A-1041 in combination with Capecitabine and Trastuzumab) and phase 1c (dose expansion with ZN-A-1041 in combination with Capecitabine and Trastuzumab).

Read the detailed description

Phase 1a of the study will adopt the "modified 3+3" dose escalation design with a total of 7 planned dose levels. Patients with HER2-positive advanced solid tumor (including those with brain metastases) will be enrolled to receive a single-dose administration of ZN-A-1041 followed by multiple-dose administration of ZN-A-1041.

Phase 1b of the study will adopt the "traditional 3+3" dose escalation design. In phase 1b, patients with HER2-positive advanced breast cancer (including those with brain metastases) will be enrolled to receive multiple doses of ZN-A-1041 in combination with Capecitabine and Trastuzumab.

In phase 1c patients with HER2-positive breast cancer with brain metastases were planned to be enrolled to receive ZN-A-1041 in combination with Capecitabine and Trastuzumab The dose levels will be determined based on the recommended doses obtained from the Phase 1b study, and the possible changes in the dosage form and the food effect study, which will be decided by the sponsor and the investigator after discussion.

Each phase of the study includes a screening period, a treatment period and a follow-up period. During the trial, the safety, tolerability, PK and efficacy data of ZN-A-1041 as monotherapy and in combination with Capecitabine and Trastuzumab in the subjects will be collected and analyzed, thereby providing RP2D for the subsequent clinical trials.

03

Conditions studied

  • Advanced Solid Tumors
  • HER2-positive Breast Cancer

Browse trials for

Keywords

  • Phase 1
  • Advanced Solid Tumors
  • HER2-Positive Breast Cancer
  • Brain metastases
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key inclusion criteria:

11. performance status of 0 to 1 2. -positive is defined as Immunohistochemistry (IHC) (++) and Fluorescence In Situ Hybridization (FISH) positive, or IHC (+++).

3. Phase 1a study will enroll patients with unresectable or HER2-positive advanced solid tumor; Phase 1b study will enroll patients with unresectable locally-advanced or metastatic HER2+ breast cancer.

i. For patients who have no , the following criteria should be met:

  1. Patients should be to existing therapy(ies) or have been intolerant of such therapies
  2. Have at least one extracranial by v1. 1 ii. For patients with brain metastasis, the following criteria should be met:

1) Have received prior treatment or patient declined the above treatment; 2) Patients with HER2-positive gastric cancer must have previously received Trastuzumab 3) Do not require immediate local treatment during the trial period, and meet either of the following two criteria:

  1. For patients who have received previous local treatment (surgery, whole brain radiotherapy (WBRT) and stereotactic radiosurgery (SRS)) for brain metastases, stable or progression of intracranial lesions is required. Interval from prior local therapy could be 3 weeks from WBRT and 2 weeks from SRS.
  2. Symptomatic or not, patient has not received previous local treatment (surgery or radiotherapy) for brain metastases as long as no local therapy is needed during the trial period.

iii. In Phase 1a, for patients who have received previous tyrosine kinase inhibitor (TKI) treatment, chemotherapy, antibody, or antibody-drug conjugate (ADC), the interval between the last treatment and the first administration of the study drug in this trial should be at least 2 weeks. In Phase 1b, for patients who have received previous trastuzumab or other antibodies, the interval between the last treatment and the first administration of the study drug in this trial should be at least 3 weeks.

4. Phase 1c study will enroll patients with unresectable locally-advanced or metastatic HER2+ breast cancer with brain metastases.

i. For patients with brain metastasis, patients do not require immediate local treatment during the trial period, and meet either of the following two criteria:

  1. For patients who have received previous local treatment (surgery, whole brain radiotherapy (WBRT) and stereotactic radiosurgery (SRS)) for brain metastases, stable or progression of intracranial lesions is required. Interval from prior local therapy could be 3 weeks from WBRT, 2 weeks from SRS and 4 weeks from surgery
  2. Symptomatic or not, patient has not received previous local treatment (surgery or radiotherapy) for brain metastases as long as no local therapy is needed during the trial period
  3. Have at least one measurable lesion and is suitable for accurate repeated assessable by RECIST 1.1, and the patient has an imaging-diagnosable intracranial lesion;
  4. Patients should not include suspected or confirmed meningeal metastases;
  5. The patient had no disease progression with previous 12 weeks' capecitabine therapy;
  6. No capecitabine therapy within 6 months;
  7. Patient should not previously treat with a tyrosine kinase inhibitor (TKI). Previous treatment with trastuzumab or other antibodies should be at least 3 weeks apart from the first treatment

Key exclusion criteria:

  1. Subjects who have participated in any clinical study or received any clinical study drug within 4 weeks prior to the first administration
  2. There is evidence that other primary tumors are present at the same time;
  3. Previous cumulative dose of doxorubicin exceeds 360mg/m2 or its equivalent dose of similar drugs;
  4. CNS Exclusion - Based on screening brain MRI and clinical assessment

    1. Progressive neurologic impairment or increased intracranial pressure (including nausea, vomiting, blurred vision, headache, epilepsy, etc.)
    2. Any intracranial lesion thought to require immediate local therapy
    3. Require antiepileptic treatment (except for these patients with stable seizures require continuous Levetiracetam therapy).
    4. Ongoing use of systemic for control of symptoms of brain metastases at a total daily dose of > 2 mg of dexamethasone (or equivalent)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    ZN-A-1041 50mg

    Phase 1a: Subjects will be given ZN-A-1041 orally 50mg Bid, for 21days as one cycle

    Drug: ZN-A-1041 50mg BID

  • Experimental
    ZN-A-1041 100mg

    Phase 1a: Subjects will be given ZN-A-1041 orally 100mg Bid, for 21days as one cycle

    Drug: ZN-A-1041 100mg BID

  • Experimental
    ZN-A-1041 200mg

    Phase 1a: Subjects will be given ZN-A-1041 orally 200mg Bid, for 21days as one cycle

    Drug: ZN-A-1041 200mg BID

  • Experimental
    ZN-A-1041 400mg

    Phase 1a: Subjects will be given ZN-A-1041 orally 400mg Bid, for 21days as one cycle

    Drug: ZN-A-1041 400mg BID

  • Experimental
    ZN-A-1041 600mg

    Phase 1a: Subjects will be given ZN-A-1041 orally 600mg Bid, for 21days as one cycle

    Drug: ZN-A-1041 600mg BID

  • Experimental
    ZN-A-1041 800mg

    Phase 1a: Subjects will be given ZN-A-1041 orally 800mg Bid, for 21days as one cycle

    Drug: ZN-A-1041 800mg BID

  • Experimental
    ZN-A-1041 1000mg

    Phase 1a: Subjects will be given ZN-A-1041 orally 1000mg Bid, for 21days as one cycle

    Drug: ZN-A-1041 1000mg BID

  • Experimental
    ZN-A-1041 level 1+Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle

    Phase 1b: ZN-A-1041 Level 1 (The previous dose of MTD) to be used in the combination therapy will be determined based on the MTD identified in the Phase 1a study. Capecitabine will be given at the dose of 1000 mg/m2, BID (2000 mg/m2/day), during the first 2 weeks of the 21-day treatment cycle. Trastuzumab (8 mg/kg in cycle 1 followed by 6 mg/kg beginning in cycle 2, administered as an IV infusion. If intolerance, reduce Capecitabine dose to 750 mg/m2 for exploration

    Drug: ZN-A-1041 Level 1 +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle

  • Experimental
    ZN-A-1041 level 2+Capecitabine 1000 mg/m2+ Trastuzumab 8 mg/kg iv. First Cycle

    Phase 1b: ZN-A-1041 Level 2 ( dose of MTD) to be used in the combination therapy will be determined based on the MTD identified in the Phase 1a study. Capecitabine will be given at the dose of 1000 mg/m2, BID (2000 mg/m2/day), during the first 2 weeks of the 21-day treatment cycle. Trastuzumab (8 mg/kg in cycle 1 followed by 6 mg/kg beginning in cycle 2, administered as an IV infusion. If intolerance, reduce Capecitabine dose to 750 mg/m2 for exploration

    Drug: ZN-A-1041 Level 2 +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle

  • Experimental
    ZN-A-1041 MAD+Capecitabine 1000 mg/m2+Trastuzumab 8 mg/kg iv. First Cycle

    Phase 1b: If the MTD is still not reached at the maximum dose level in Phase 1a study, the maximum dose level (MAD) of ZN-A-1041 in Phase 1a will be used in Phase 1b study. If intolerance, reduce Capecitabine dose to 750 mg/m2 for exploration

    Drug: ZN-A-1041 MAD +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle

  • Experimental
    ZN-A-1041+Capecitabine+Trastuzumab

    Phase 1c: The combined dose of ZN-A-1041 is based on the recommended combined dose in the Phase 1b and the possible changes in the dosage form and the results of the food effect study, which will be decided by the sponsor and the investigator after discussion

    Drug: ZN-A-1041+Capecitabine + Trastuzumab 8 mg/kg iv. First Cycle

Interventions

  • Orally 21days for one cycle

    Also known as: ZN-A-1041 Enteric Capsules

  • Orally 21days for one cycle

    Also known as: ZN-A-1041 Enteric Capsules

  • Orally 21days for one cycle

    Also known as: ZN-A-1041 Enteric Capsules

  • Orally 21days for one cycle

    Also known as: ZN-A-1041 Enteric Capsules

  • Orally 21days for one cycle

    Also known as: ZN-A-1041 Enteric Capsules

  • Orally 21days for one cycle

    Also known as: ZN-A-1041 Enteric Capsules

  • Orally 21days for one cycle

    Also known as: ZN-A-1041 Enteric Capsules

  • DrugZN-A-1041 Level 1 +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle

    Drug page: Bizrolertinib

    ZN-A-1041 level 1 BID; Capecitabine 1000 mg/m2 BID Trastuzumab 8 mg/kg iv. First Cycle

    Also known as: ZN-A-1041 Enteric Capsules

  • DrugZN-A-1041 Level 2 +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle

    Drug page: Bizrolertinib

    ZN-A-1041 level 2 BID; Capecitabine 1000 mg/m2 BID Trastuzumab 8 mg/kg iv. First Cycle

    Also known as: ZN-A-1041 Enteric Capsules

  • DrugZN-A-1041 MAD +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle

    Drug page: Bizrolertinib

    ZN-A-1041 MAD BID; Capecitabine 1000 mg/m2 BID Trastuzumab 8 mg/kg iv. First Cycle

    Also known as: ZN-A-1041 Enteric Capsules

  • DrugZN-A-1041+Capecitabine + Trastuzumab 8 mg/kg iv. First Cycle

    Drug page: Bizrolertinib

    Base on 1b ZN-A-1041 dose Base on 1b Capecitabine dose Base on 1b Trastuzumab dose

    Also known as: ZN-A-1041 Enteric Capsules

This study also gives Trastuzumab. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. The safety/tolerability of ZN-A-1041 as a monotherapy on Phase 1a

    Dose at which no more than one out of six patient at the same dose level experiences a probable drug-related dose limiting toxicity.

    Time frame: 23days

  2. The safety/tolerability of ZN-A-1041 in combination with Capecitabine and Trastuzumab in Phase 1b

    Dose at which no more than one out of six patient at the same dose level experiences a probable drug-related dose limiting toxicity.

    Time frame: 21days

  3. The safety of ZN-A-1041 in combination with Capecitabine and Trastuzumab in Phase 1c

    To evaluate the safety of ZN-A-1041 in combination with Capecitabine in patients on the RP2D Dose

    Time frame: through study completion, an average of 3 year

Secondary outcomes

  1. Plasma Level of ZN-A-1041 and its major metabolites on phase 1a,phase 1b and 1c

    To assess the AUC of ZN-A-1041 and its major metabolites;

    Time frame: From baseline to Day 8

  2. Plasma Level of ZN-A-1041 and its major metabolites on Phase 1a,phase 1 b and 1c

    To assess the Cmax of ZN-A-1041 and its major metabolites;

    Time frame: From baseline to Day 8

  3. Plasma level of ZN-A-1041 and its main metabolites Phase 1a,phase 1b and 1c

    To assess the Tmax of ZN-A-1041 and its major metabolites;

    Time frame: From baseline to Day 8

  4. The preliminary efficacy of ZN-A-1041 as a monotherapy or combination in Phase 1a,phase 1b and 1c

    overall Response Rate (ORR);Progression free survival(PFS)

    Time frame: through study completion, an average of 3 year

07

Study locations

1 site
  • Cancer hospital Chinese academy of medical sciences
    Beijing, Beijing Municipality 100000, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Apr 2024, 42 months.

Of 204 phase 1 interventional studies under Brain Neoplasms, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 84. This study's 42 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2020
First posted
Jul 27, 2020
StartActual
Oct 15, 2020
Primary completionActual
Apr 16, 2024
CompletionActual
Apr 16, 2025
Last update
Aug 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04487236
Lead sponsor
Suzhou Zanrong Pharma Limited
Responsible party
Sponsor
First posted
Jul 27, 2020
Start date
Oct 15, 2020
Primary completion
Apr 16, 2024
Completion
Apr 16, 2025
Last update
Aug 11, 2025

Study contacts

Fei Ma, MD
principal investigator · Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bizrolertinib

Start the discussion